IRS2 and metabolic dysfunction-associated steatotic liver disease: In this study, we investigated the effects of lncARSR/YAP1 on NAFLD, and finally identified that lncARSR promoted NAFLD through YAP1 and the IRS2/AKT pathway, thus providing a novel insight into NAFLD treatment.